Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Equity Ratio (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Equity Ratio readings, the most recent being 0.71 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 19.2% to 0.71 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.71, a 19.2% decrease, with the full-year FY2025 number at 0.71, down 19.2% from a year prior.
  • Equity Ratio hit 0.71 in Q4 2025 for Avalo Therapeutics, down from 0.73 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2025 to a low of 0.91 in Q1 2024.
  • Median Equity Ratio over the past 5 years was 0.31 (2021), compared with a mean of 0.24.
  • Biggest five-year swings in Equity Ratio: surged 1004.75% in 2023 and later crashed 425.91% in 2024.
  • Avalo Therapeutics' Equity Ratio stood at 0.29 in 2021, then tumbled by 213.68% to 0.33 in 2022, then surged by 206.36% to 0.35 in 2023, then surged by 153.67% to 0.88 in 2024, then dropped by 19.2% to 0.71 in 2025.
  • The last three reported values for Equity Ratio were 0.71 (Q4 2025), 0.73 (Q3 2025), and 0.83 (Q2 2025) per Business Quant data.